Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of ViroPharma, Inc. (“ViroPharma” or the “Company”) (Nasdaq: VPHM) relating to the proposed acquisition by Shire PLC (“Shire”). Click here to learn more about the investigation http://brodsky-smith.com/675-vphm-viropharma-inc.html, or call 877-534-2590. There is no cost or obligation to you. Under the terms of the transaction, ViroPharma shareholders will receive only $50.00 in cash for each share of ViroPharma stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of ViroPharma for not acting in the Company’s shareholders' best interests in connection with the sale process. The investigation seeks to determine if the ViroPharma Board of Directors failed to conduct an adequate auction process and as a result harmed the ViroPharma shareholders by undervaluing their Company. If you own shares of ViroPharma common stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at email@example.com, by visiting http://brodsky-smith.com/675-vphm-viropharma-inc.html, or calling toll free 877-LEGAL-90. Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and case action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.